Transcode Therapeutics Inc (RNAZ) FinancialsRNAZFinancialTranscode Therapeutics Inc

In the context of the broader market, RNAZ competes directly with industry leaders such as QNTM and ELUT. With a market capitalization of $9.90M, it holds a significant position in the sector. When comparing efficiency, RNAZ's gross margin of N/A stands against QNTM's N/A and ELUT's 57.87%. Such benchmarking helps identify whether Transcode Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Transcode Therapeutics has shown consistently negative net income over the past quarters, with Q2 2026 net income at -6,865,143. The company has a current ratio of 1.97, indicating it can cover its short-term liabilities, but the overall financial outlook remains bleak with a total equity of -27,694,917 in Q2 2026.